TheracosBio aims to challenge Big Pharma blockbusters with newly-approved SGLT2 for diabetes

Beth Snyder Bulik

Senior Editor

TheracosBio is squaring up for its little-engine-that-could moment. Its type 2 diabetes med Brenzavvy nabbed FDA approval on Friday, landing the privately-funded, little-known biotech in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TheracosBio aims to challenge Big Pharma blockbusters with newly-approved SGLT2 for diabetes

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ther­a­cos­Bio aims to chal­lenge Big Phar­ma block­busters with new­ly-ap­proved SGLT2 for di­a­betes

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

TheracosBio aims to challenge Big Pharma blockbusters with newly-approved SGLT2 for diabetes